The tumor‐formation ability of AML CSCs was potently inhibited in immunodeficient mice following JAK1/2 inhibitor treatment,125 reinforcing the promoting effect of JAK/STAT signaling on CSC stemness across a wide panel of cancers.126. The gene discussed is SOAT1; the disease is acute myeloid leukemia.